Amgen posts results for terminated acapatamab mCRPC trial; updates MARITIME-PEN and AMG 691 recordsNov 13Weekly roundup, 6 itemsacapatamabAMG-691Updated
FDA's traditional approval for Imdelltra followed 2024 accelerated nodNov 12Regulatory decisionAmgentarlatamab-dlleUpdated
FDA accelerated approval for Enhertu in HER2-positive solid tumors, dated April 5, 2024Nov 9Regulatory decisionAmgenDaiichi Sankyo
FDA approves blinatumomab for consolidation in Ph-negative B-cell precursor ALLNov 6Regulatory decisionAmgenblinatumomab
Amgen gets Amjevita label update; registers Phase 3 MariTide trial against semaglutideNov 6Weekly roundup, 5 itemsadalimumab-attoAmgenUpdated
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
GSK's Benlysta label updated by FDA; Phase 2a NASH trial posts resultsOct 30Weekly roundup, 10 itemsaletekitugAmgenUpdated
Amgen's MariTide cardiovascular outcomes trial surfaces; OASIS pediatric migraine results holdOct 29Weekly roundup, 2 itemsAmgenmaridebart cafraglutideUpdated
Amgen posts results for completed Phase 4 romosozumab and Phase 1 rocatinlimab trialsOct 23Weekly roundup, 4 itemsAmgenrocatinlimabUpdated
FDA records second original approval for Amgen's PavbluOct 22Regulatory decisionaflibercept-ayyhAmgen
Amgen registers Phase 2/3 inebilizumab trial in autoimmune hepatitisOct 16Weekly roundup, 3 itemsAmgenetanerceptUpdated
MD Anderson's phase 2 trial of subcutaneous blinatumomab in MRD-positive B-ALL listed as suspendedOct 8Trial updateAmgenblinatumomab
Amgen registers new Phase 3 maridebart cafraglutide vs. semaglutide trial in type 2 diabetesOct 8Weekly roundup, 3 itemsAMG-513AmgenUpdated
Amgen gets FDA biosimilar supplement approval for RIABNI; posts new evolocumab PK trialOct 2Weekly roundup, 5 itemsAmgenapremilastUpdated
FDA approves label update for TEPEZZA; Amgen registers MariTide bioavailability studySep 23Weekly roundup, 2 itemsAmgenmaridebart cafraglutide
Amgen updates IMDELLTRA label via BLA supplement; registers romosozumab bioavailability trialSep 11Weekly roundup, 2 itemsAmgenromosozumab-aqqg
Amgen registers Phase 4 trial testing Repatha's effect on coronary plaque burdenSep 4Trial updateAmgenevolocumab